MaxCyte Share Forecast, Price & News

MaxCyte (LON:MXCT) Frequently Asked Questions

Is MaxCyte a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MaxCyte in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MaxCyte stock.
View analyst ratings for MaxCyte or view top-rated stocks.

How has MaxCyte's stock been impacted by COVID-19?

MaxCyte's stock was trading at GBX 150 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MXCT stock has increased by 400.0% and is now trading at GBX 750.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for MXCT?

1 Wall Street analysts have issued 1-year price objectives for MaxCyte's stock. Their forecasts range from GBX 1,240 to GBX 1,240. On average, they anticipate MaxCyte's stock price to reach GBX 1,240 in the next year. This suggests a possible upside of 65.3% from the stock's current price.
View analysts' price targets for MaxCyte or view top-rated stocks among Wall Street analysts.

Who are MaxCyte's key executives?

MaxCyte's management team includes the following people:

• Mr. Douglas Arthur Doerfler, Founder, Pres, CEO & Exec. Director (Age 65, Pay $705.25k)
• Mr. Ronald Evan Holtz Ph.D., CPA, Sr. VP, Chief Accounting Officer, Company Sec. & Exec. Director (Age 63, Pay $445.93k)
• Ms. Amanda Louise Murphy C.F.A., CFA, Chief Financial Officer
• Mr. Maher Masoud, Exec. VP & Gen. Counsel
• Mr. Thomas Michael Ross, Exec. VP of Global Sales (Age 60)
• Mr. Markus J. Hunkeler, VP of Marketing
• Dr. Claudio Dansky Ullmann M.D., Chief Medical Officer
• Ms. Shruti Abbato, Exec. VP of Bus. Devel. for CARMA Cellular Therapies

Who are some of MaxCyte's key competitors?

Some companies that are related to MaxCyte include Renalytix AI (RENX), Sernova (SVA), Profound Medical (PRN), Akumin (AKU), Oncimmune (ONC), Profound Medical (PRN), Yourgene Health (YGEN), Verici Dx (VRCI), SQI Diagnostics (SQD), LexaGene (LXG), VentriPoint Diagnostics (VPT), Cambridge Cognition (COG), genedrive (GDR), GeneNews (GEN) and Abingdon Health (ABDX).
View all of MXCT's competitors.

What other stocks do shareholders of MaxCyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MaxCyte investors own include boohoo group (BOO), Juno Therapeutics (JUNO), (ATE), Astrotech (ASTC), Arcturus Therapeutics (ARCT), (AQB), Aptose Biosciences (APTO), Appili Therapeutics (APLIF), Argan (AGX) and Applied Genetic Technologies (AGTC).

What is MaxCyte's stock symbol?

MaxCyte trades on the London Stock Exchange (LON) under the ticker symbol "MXCT."

How do I buy shares of MaxCyte?

Shares of MXCT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is MaxCyte's stock price today?

One share of MXCT stock can currently be purchased for approximately GBX 750.

How much money does MaxCyte make?

MaxCyte has a market capitalization of £755.73 million and generates £32.26 million in revenue each year.

How many employees does MaxCyte have?

MaxCyte employs 65 workers across the globe.

What is MaxCyte's official website?

The official website for MaxCyte is www.maxcyte.com.

Where are MaxCyte's headquarters?

MaxCyte is headquartered at 22 Firstfield Rd Ste 110, GAITHERSBURG, MD 20878-1795, United States.

How can I contact MaxCyte?

MaxCyte's mailing address is 22 Firstfield Rd Ste 110, GAITHERSBURG, MD 20878-1795, United States. The company can be reached via phone at +1-301-9441700.